Valuation: Scholar Rock Holding Corporation

Market Cap 4.9B 4.37B 4.05B 3.68B 6.9B 465B 7.02B 48.54B 19.09B 243B 18.39B 18B 776B P/E 2026 *
-12.3x
P/E 2027 * -15.6x
Enterprise Value 4.58B 4.09B 3.79B 3.44B 6.46B 435B 6.56B 45.4B 17.85B 227B 17.2B 16.84B 726B EV / Sales 2026 *
807x
EV / Sales 2027 * 31.6x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Scholar Rock Holding Corporation

1 day+0.85%
1 week-4.05%
Current month-16.72%
1 month-13.74%
3 months-23.87%
6 months-19.46%
Current year-8.65%
1 week 38.69
Extreme 38.69
41.35
1 month 38.69
Extreme 38.69
51.74
Current year 38.69
Extreme 38.69
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 6.76
Extreme 6.76
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/24/26 Don

Chief Operating Officer

-48,034 0.0394%
9/21/26 Don

Chief Executive Officer

-36,652 0.0301%
7/1/26 Sell

Director

-2,544 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+0.85%-4.05%+44.02%+436.53% 4.86B
+1.52%-7.19%+51.66%+69.99% 65B
+1.52%+6.83%+10.77%+79.30% 51.2B
+0.30%-0.46%+2.53%+61.89% 51.19B
-0.38%+1.40%+29.98%+42.37% 43.93B
+0.30%+5.64%+16.99%+133.30% 41.96B
+2.35%-6.08%+236.69%+528.10% 38.14B
+2.16%+9.87%+18.92%+59.70% 33.24B
+5.91%-0.59%+41.69%+10.52% 25.2B
+1.60%+2.21%+21.34%+28.00% 22.5B
Average +1.59%-0.44%+47.46%+144.97% 37.72B
Weighted average by Cap. +1.41%-0.21%+46.31%+117.64%

Financials

2026 *2027 *
Net sales 5.68M 5.06M 4.69M 4.26M 8M 538M 8.13M 56.23M 22.11M 281M 21.3M 20.86M 899M 142M 127M 117M 107M 200M 13.48B 204M 1.41B 554M 7.05B 533M 522M 22.52B
Net income -430M -383M -355M -323M -606M -40.75B -616M -4.26B -1.67B -21.3B -1.61B -1.58B -68.09B -360M -321M -297M -270M -507M -34.1B -515M -3.56B -1.4B -17.82B -1.35B -1.32B -56.98B
Net Debt -316M -282M -261M -238M -446M -30B -453M -3.13B -1.23B -15.68B -1.19B -1.16B -50.13B -410M -366M -339M -308M -578M -38.91B -588M -4.06B -1.6B -20.34B -1.54B -1.51B -65.01B
Projected Income Statement - Annual - Scholar Rock Holding Corporation
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-10-19 $40.24 +0.85% 1,480,188
26-10-16 $39.90 -1.82% 2,894,039
26-10-15 $40.64 +2.63% 1,944,767
26-10-14 $39.60 -2.27% 1,278,096
26-10-13 $40.52 -3.39% 1,096,269
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Scholar Rock Holding Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
40.24USD
Average target price
70.44USD
Spread / Average Target
+75.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Scholar Rock Holding Corporation
  1. Stock Market
  2. Stocks
  3. SRRK Stock